09:50:11 EST Tue 07 Feb 2023
Enter Symbol
or Name

Login ID:
Isodiol International Inc (2)
Symbol ISOL
Shares Issued 80,543,692
Close 2020-12-09 C$ 0.035
Recent Sedar Documents

Isodiol sues buyer of former BSPG subsidiary

2021-01-07 20:03 ET - Street Wire

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Mike Caswell

Isodiol International Inc., a would-be developer of CBD products, has filed a lawsuit in the Supreme Court of British Columbia to collect money owing from a deal to sell its BSPG Laboratories Ltd. subsidiary. Isodiol claims that the purchaser has failed to pay $2.25-million of the $14-million purchase price. (All figure are in U.S. dollars.) The company is seeking the court-ordered payment.

The lawsuit adds one more chapter to a venture Isodiol would undoubtedly prefer to leave behind. The company purchased BSPG and another entity for $43-million on April 17, 2018, satisfying most of the purchase price with shares. Less than a year later, Isodiol abruptly sold BSPG, in the process recording a $19-million loss on the business. In entering the "bittersweet" transaction, Isodiol chief executive officer Marcos Agramont cited problems raising money for BSPG.

The transaction looked to be the end of BSPG for Isodiol, until the present lawsuit. On Dec. 31, 2020, Isodiol filed a notice of claim against the buyer at the Vancouver courthouse. The sole defendant is Brain Bioceutical Corp., which had agreed to purchase BSPG on March 29, 2019. The problems, as set out in the suit, stemmed from staged payments that were to be completed by Sept. 30, 2020.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

© 2023 Canjex Publishing Ltd. All rights reserved.

Reader Comments - Comments are open to paying subscribers of Stockwatch and unmoderated, although libelous remarks, obscene language and impersonations may be deleted. Opinions expressed do not necessarily reflect the views of Stockwatch.
For information regarding Canadian libel law, please view the University of Ottawa's FAQ regarding Defamation and SLAPPs.

Comments for this item are closed